ROS1 and liposarcoma: ROS1 fusions were seen in 14 patients in the STS cohort – dedifferentiated liposarcoma (n=4), inflammatory myofibroblastic tumor (n=4), leiomyosarcoma (n=1), liposarcoma (n=1), myxoid/round cell liposarcoma (n=1), PEComa (n=1), synovial sarcoma (n=1), undifferentiated pleomorphic sarcoma (n=1) –, and one patient in the bone sarcoma cohort (osteosarcoma).